Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, cinacalcet (Mimpara™) cannot be endorsed for use within NHS Wales for the treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. |
||
|
||
Medicine details |
||
| Medicine name | cinacalcet (Mimpara™) | |
| Formulation | 30 mg, 60 mg and 90 mg filmcoated tablets and 1 mg, 2.5 mg and 5 mg granules | |
| Reference number | 3294 | |
| Indication | Treatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy. |
|
| Company | Amgen Ltd | |
| BNF chapter | Nutrition & blood | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 28/11/2017 | |